Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2014

View Archived Issues

Researchers present phase III clinical data for ZS-9 as treatment of hyperkalemia

Promising phase IIb results presented from the TIME trial evaluating TG-4010 in NSCLC

AB Science selects SYK kinase inhibitor AB-8779 for full preclinical development

Pfizer initiates phase II trial of PF-05089771 in painful diabetic peripheral neuropathy

Novel CDK4 and/or CDK6 inhibitors disclosed by Jiangsu Hengrui Medicine

Roche divulges novel RSV fusion protein inhibitors

Nerviano Medical Sciences synthesizes novel Ret inhibitors

Curadev Pharma discloses new IDO and/or TDO regulators

Fudan University presents novel hedgehog signaling inhibitors

Calzada changes name to PolyNovo

E.U. regulatory authorities investigate adverse events in patients who received Fluad

Icosabutate shows promise as lipid-lowering agent in animal studies and early clinical trials

Karyopharm confirms additional orphan designations for selinexor in the E.U.

Ixazomib granted FDA breakthrough therapy designation in systemic light-chain amyloidosis

Necuparanib receives FDA fast track designation for metastatic pancreatic cancer

Novartis prepares for Japanese launch of Stalevo tablets

GlaxoSmithKline presents preclinical data for the anti-HER3 antibody GSK-2849330

FDA grants fast track status to palovarotene for fibrodysplasia ossificans progressiva

FDA lifts clinical hold on FX-006 for osteoarthritis pain

Cabozantinib misses pain endpoint in COMET-2 mCRPC trial

Compound inhibiting SSAO may improve Parkinson's disease

FDA approves Priftin for latent tuberculosis infection

European marketing authorization for Xtandi extended to chemotherapy-naive prostate cancer

Baxter files BLA for BAX-855 for hemophilia A

EMA grants ALS candidate TW-001 orphan drug designation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...